Ensuring all relevant target subgroups inform healthcare decisions for all stakeholders has shifted from a “hot topic” to a core consideration. The United States Food and Drug Administration guidance on Diversity Trial Plans opened the door for other regulatory, health technology assessment agencies and payers worldwide to request data and analyses in product submissions that represent a wider population including otherwise under-represented patients, real-life population, thus driving better patient outcomes and value care for all. The pharmaceutical industry has responded by initiating steps to consider how health equity can be integrated into market access strategies.

Key topics

• The value of health equity to payers and other decision-makers
• Overview of guidance and frameworks on diversity and health equity in healthcare and key gaps
• Diversity Action Plans and the associated requirements for trials and observational studies submitted for approval
• Mapping of health equity considerations (e.g., real-world data sources) and methods (e.g., data transferability across borders, distributed cost-effectiveness analyses) across the evidence lifecycle
• Presentation of real case-studies
• Opportunities for methods innovation in health equity for product launch

Speakers

• Grammati Sarri, PhD, Executive Research Principal
• Lydia Vinals, PhD, Associate Director, Research Principal
• Lilia Leisle, PhD, Senior Research Consultant
• Jeff Muir, DC, MSc, Senior Research Consultant
• Natalie Horowicz-Mehler, PhD, VP & Global Head of Value